共 50 条
- [3] Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis JOURNAL OF CROHNS & COLITIS, 2023, 17 : 598 - 598
- [4] Association of Faecal Calprotectin With Symptomatic, Endoscopic, and Clinical Remission in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Mirikizumab AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S958 - S958
- [5] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
- [7] Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1042 - S1043